What I Do and Why: HBV Treatment Strategies for Diverse Patient Populations

Deciding which patients with chronic hepatitis B should be treated is not as simple as determining if their ALT and DNA levels fall above guideline thresholds. Here’s my take.

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director Released: April 6, 2020

Preventing mother-to-child transmission of HBV infection is critical to ensure the long-term health of the newborn. Here’s how we can prevent infection in infants born to mothers with HBV infection.

Maria Buti, MD Released: April 29, 2020

The early detection of HCC in patients with chronic HBV infection means the difference between curable vs terminal disease. Here is how I ensure I do not miss HCC in my patients.

Steven L. Flamm, MD Released: June 16, 2020

What are the pros and cons of discontinuing oral therapy with nucleos(t)ide analogues in patients with chronic HBV infection? Here’s my take.

Pietro Lampertico, MD, PhD Released: July 10, 2020

How do you distinguish between patients who are true inactive carriers and those with immune active HBeAg-negative chronic hepatitis B? Here’s my take.

Anna Christina L. dela Cruz, MD Released: August 18, 2020